Work

Phase II Trial of Murine 131I-Labeled Antitenascin Monoclonal Antibody 81C6 Administered Into Surgically Created Resection Cavities of Patients With Newly Diagnosed Malignant Gliomas

Year: 2002

Type: article

Study design: Clinical Trial

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2002.20.5.1389

Authors: David A. Reardon, Gamal Akabani, R. Edward Coleman, Allan H. Friedman, Henry S. Friedman, James E. Herndon, Ilkcan Cokgor, Roger E. McLendon, Charles N. Pegram, James M. Provenzale, Jennifer A. Quinn, Jeremy N. Rich, Lorna V. Regalado, John H. Sampson, Timothy D. Shafman, Carol J. Wikstrand, Terence Z. Wong, Xiao-Guang Zhao, Michael R. Zalutsky, Darell D. Bigner

Institutions: Duke University, Duke Medical Center, University of California, Davis

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: National Cancer Institute, National Institute of Neurological Disorders and Stroke, National Center for Research Resources

Awards: G460175554, G488511823, G4946238614

OpenAlex ID: W4252608787

FWCI: 6.355

Cites: 27

Cited by: 152

Related to: 10